The Journal of Life Sciences

Last updated
The Journal of Life Sciences
Editor-in-chiefWilliam Patrick
FrequencyBimonthly
Publisher
First issueMay 2007
Company
CountryUSA
Website http://www.tjols.com/

The Journal of Life Sciences is a full-color bimonthly American magazine and daily website published in San Francisco since May 2007. Owned by Burrill & Company [1] [ failed verification ] and the California Healthcare Institute, [2] [ failed verification ] TJOLS reports on how developments in the life sciences affect society, business, and policy.

TJOLS was launched to cover topics "where science and society meet"—an area that its founders felt was often overlooked by peer-reviewed science journals and mainstream business publications. Printed in a digest format, TJOLS was designed to stand apart from other science magazines on the rack with illustrated covers and its reliance on photography to help tell stories. The magazine has been well received by biotechnology executives, policy wonks, and healthcare professionals.[ citation needed ]

From March 2007 to November 2007, TJOLS was published in partnership with Nielsen Business Media. Since that agreement ended in November 2007, the property has been owned jointly by Burrill & Company, a San Francisco-based life sciences merchant bank and the California Healthcare Institute, a public policy research and advocacy organization representing California's biotech community based in La Jolla, California.

History

Longtime biotechnology investor G. Steven Burrill, CEO of life sciences merchant bank Burrill & Company, and David Gollaher, president of the California Healthcare Institute, a biotech trade group, first began efforts to develop TJOLS in 2006. The idea for the magazine was strongly influenced by The Acumen Journal of Life Sciences, a now-defunct publication that covered themes similar to TJOLS' and was published between 2003 and 2004. Burrill & Company and the California Healthcare Institute provided startup funding, along with members of the magazine's advisory board. A prototype was first published in November 2006, but the design and logo were scrapped in favor of TJOLS' current digest format and yellow-and-black logo.

In March 2007, Nielsen Business Media invested in TJOLS in a move to expand its media presence in the life sciences. The magazine was formally launched in May at BIO, the world's largest biotechnology conference held in 2007 in Boston. Five issues of the magazine, which is distributed free of charge to people who qualify, were printed in 2007. In November 2007, Nielsen ended its partnership with TJOLS.

The co-publishers of TJOLS are G. Steven Burrill, CEO of life sciences merchant bank Burrill & Company, and David Gollaher, president of the California Healthcare Institute, a biotech trade group. William Patrick, TJOLS' editor-in-chief, is the former science and medicine editor at Harvard University Press and is the co-author of a forthcoming book on the social neuroscience of loneliness Managing Editor Eric Wahlgren served on the staff of Red Herring and at Business Week Online. Web editor Daniel S. Levine, an award-winning business journalist, previously served as the biotechnology reporter for the San Francisco Business Times. He was also the founder of the online magazine Disgruntled (the business magazine for people who work for a living) and authored "Disgruntled: The Darker Side of the World of Work". [3]

Under Patrick, the magazine has sought to make the content livelier than that of most science publications, with articles on human tissue as art, home kits for genetic testing, and research on the health effects of marriage by matchmaking site eHarmony's Ph.D.'s. Recent issue covers have focused on the big current trends in the life sciences including stem cell research, personalized medicine, and health and wellness.

TJOLS contributors have included Sally Lehrman, Frank Browning, Ann Parson, Gareth Cook, Bruce Goldman, Lawrence M. Fisher, Julian Smith, Brian Vastag, Stephan Herrera, Sarah A. Klein, and K.C. Swanson.

Related Research Articles

<span class="mw-page-title-main">University of California, San Francisco</span> Public university in California, US

The University of California, San Francisco (UCSF) is a public land-grant research university in San Francisco, California. It is part of the University of California system and is dedicated entirely to health science and life science. It conducts research and teaching in medical and biological sciences.

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

Gregory Stock is an American biophysicist, best-selling author, biotech entrepreneur, and the former director of the Program on Medicine, Technology and Society at UCLA’s School of Medicine. His interests lie in the scientific and evolutionary as well as ethical, social and political implications of today's revolutions in the life sciences and in information technology and computers.

<span class="mw-page-title-main">Genome Valley</span> Life Sciences in Telangana, India

Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 kms from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).

Arthur D. Levinson is an American businessman and is the chairman of Apple Inc. (2011–present) and chief executive officer (CEO) of Calico. He is the former CEO (1995–2009) and chairman (1999–2014) of Genentech.

<span class="mw-page-title-main">Buck Institute for Research on Aging</span> US biomedical research institute

The Buck Institute for Research on Aging is an independent biomedical research institute that researches aging and age-related disease. The mission of the Buck Institute is to extend the healthy years of life. The Buck Institute is one of nine centers for aging research of the Glenn Foundation for Medical Research.

<span class="mw-page-title-main">David Ewing Duncan</span> American journalist

David Ewing Duncan is an American journalist, author, and researcher on new discoveries and their implications for the life sciences. He also writes about robots and artificial intelligence. He is the author of 12 books and a journalist for Vanity Fair, Wired, Scientific American, The Atlantic, The New York Times, MIT Technology Review, National Geographic, and other publications.

<span class="mw-page-title-main">David Gollaher</span> American historian and biotechnology executive

David L. Gollaher was the founding President & CEO of the California Healthcare Institute (CHI), 1993–2014, from which he joined Gilead Sciences. Initially, in 1998, he was a charter member of Gilead's Health Policy Advisotry Board, then, from 2014 to 2018, he served as the company's head of worldwide Government Affairs and Policy. Subsequently, in early 2019, he was appointed Senor Vice President of global policy and government affairs at Vir Biotechnology, an emerging growth biotech company focused on infectious diseases. He retired from Vir in 2021. Previously, in 2018, he was named Senior Fellow at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California.

CHI-California Healthcare Institute is a private, non-profit public policy research and advocacy organization, representing more than 250 universities, academic research centers, biotechnology, and medical device companies. Founded in 1993, and based in La Jolla, California, CHI has offices in Washington, D.C., and Sacramento, California. CHI publishes an annual California Biomedical Industry report, providing data on the scope and scale of academic and commercial life sciences research and development within the state. In 2008, the industry employed more than 270,000 Californians and produced revenues in excess of $75 billion.

<span class="mw-page-title-main">California Institute for Quantitative Biosciences</span>

The California Institute for Quantitative Biosciences (QB3) is a nonprofit research and technology commercialization institute affiliated with three University of California campuses in the San Francisco Bay Area: Berkeley, San Francisco, and Santa Cruz. QB3's domain is the quantitative biosciences: areas of biology in which advances are chiefly made by scientists applying techniques from physics, chemistry, engineering, and computer science.

<span class="mw-page-title-main">Ivor Royston</span> Researcher

Ivor Royston is an American oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.

Denise Caruso is an American journalist and analyst specializing in the industries of digital technology and biotechnology. She was dubbed “the Walter Winchell of Silicon Valley” by WIRED magazine. She is the founder and executive director of The Hybrid Vigor Institute, a non-profit think tank created in 2000 that emphasizes cross-sector collaboration.

Life Sciences Foundation (LSF) was a San Francisco-based nonprofit organization that was established in 2011 to collect, preserve, interpret, and promote the history of biotechnology. LSF conducted historical research, maintained archives and published historically relevant materials and information.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

<span class="mw-page-title-main">Geoffrey von Maltzahn</span> American inventor

Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics. He has over 200 bioengineering and biotechnology patents and applications.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

Joseph Edelman is an American hedge fund manager who founded Perceptive Advisors, a New York City-based hedge fund specializing in the healthcare sector and biotechnology. He helped take biotech firms public via the use of special-purpose acquisition companies.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Entos, Inc.. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

<span class="mw-page-title-main">Frederick Frank (businessman)</span>

Frederick Frank CFA was an investment banker, with more than 50 years of experience on Wall Street. He is considered the first investment banker to have specialized in the areas of biotechnology, pharmaceuticals, and health care services.

<span class="mw-page-title-main">Helmy Eltoukhy</span> American scientist and entrepreneur

Helmy Eltoukhy is an American scientist and a businessperson who co-founded startups Avantome and Guardant Health. He is best known for his contributions to genomics, semiconductor DNA sequencing, and personalized medicine. His startups were acquired by Illumina in 2008. Avantome was founded to develop and commercialize semiconductor-based DNA sequencing, during the race for the $1,000 genome. Guardant Health was founded to pioneer non-invasive liquid biopsy approaches for cancer diagnosis, monitoring, personalized medicine treatment, and research.

References

  1. "China online Wholesalers on burrillandco.com". www.burrillandco.com.
  2. "CLSA". California Life Sciences Association.
  3. Berkley/Boulevard Books